Tech Center 1600 • Art Units: 1627 1654
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18290347 | NEW SUBSTITUTED PYRIDINES AS FUNGICIDE | Non-Final OA | BASF SE |
| 18270581 | USE OF KRAS G12C INHIBITOR IN TREATING CANCERS | Non-Final OA | AMGEN INC. |
| 18004656 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | Final Rejection | Purdue Research Foundation |
| 17996898 | COMPOUNDS FOR THE TREATMENT OF SARS | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18251868 | INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | Non-Final OA | Brown University |
| 18250530 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | Non-Final OA | YALE UNIVERSITY |
| 17625421 | CARDIAC THERAPEUTIC | Non-Final OA | National University of Singapore |
| 17584663 | RAPID RELIEF OF MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE | Final Rejection | Merz Pharmaceuticals, LLC |
| 18034649 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | Non-Final OA | The United States Government as Represented by the Department of Veterans Affairs |
| 18396305 | COPPER CHELATOR, ANTICANCER AGENT AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR WILSON'S DISEASE | Non-Final OA | National University Corporation Hokkaido University |
| 17761737 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | Non-Final OA | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 18301475 | Benzimidazole Derivative Compounds and Uses Thereof | Non-Final OA | Pfizer Inc. |
| 18042748 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | Final Rejection | Neurocrine Biosciences, Inc. |
| 18249766 | METALLIC TRANS-(N-HETEROCYCLIC CARBENE)-AMINE-PLATINUM COMPLEXES AND USES THEREOF FOR TREATING CANCER | Non-Final OA | UNIVERSITE PARIS-SACLAY |
| 18265063 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | Non-Final OA | Cancer Research Technology Limited |
| 17906557 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | Non-Final OA | MEDSHINE DISCOVERY INC. |
| 18565673 | USE OF COMPOSITION OF ALCOHOL AND COOLING AGENT IN REGULATING SEXUAL FUNCTIONS, PROTECTING CARDIOVASCULAR AND CEREBROVASCULAR SYSTEMS, PROMOTING REGENERATION OF LIVER CELLS, PREVENTING AND/OR TREATING TUMORS, AND IMPROVING IMMUNITY AND SLEEP QUALITY | Non-Final OA | QINGHAI SPRING MEDICINAL RESOURCES TECHNOLOGY CO.,LTD. |
| 18562643 | USE OF PYRROLOPYRIMIDINE COMPOUND | Non-Final OA | GUANGZHOU JOYO PHARMATECH CO., LTD |
| 18559951 | FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | Non-Final OA | Addex Pharma S.A. |
| 18560076 | NOVEL FORMS OF ENTINOSTAT | Non-Final OA | Macfarlan Smith Limited |
| 18559411 | USE OF CLOFOCTOL FOR THE TREATMENT OF INFLAMMATION | Non-Final OA | APTEEUS |
| 17757530 | COMBINATIONS | Final Rejection | Recurium IP Holdings, LLC |
| 18471563 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Non-Final OA | Monte Rosa Therapeutics AG |
| 18266970 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | Non-Final OA | NeuBase Therapeutics, Inc. |
| 17996113 | MOLECULES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Final Rejection | UNIVERSITA' DEGLI STUDI DI MILANO |
| 18196962 | INHALED LIQUID FOR THE TREATMENT OF RESPIRATORY INFECTIONS IN HUMANS CAUSED BY PATHOGENS RESISTANT TO ANTIBIOTICS | Non-Final OA | CONICK BIOTECH LLC |
| 17773861 | Metal Complexes Bearing Bisstyryl-Bipyridine Ligand and Their Use as Photosensitizer Agent in One and Two-Photon Photodynamic Therapy | Final Rejection | Ecole Nationale Superieure de Chimie de Paris |
| 17802719 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | Final Rejection | REMIX THERAPEUTICS INC. |
| 18032998 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Non-Final OA | Zoetis LLC |
| 18030211 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | Antares Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy